Tag Archives: Edward White

H.C. Wainwright Reiterates Their Buy Rating on Celyad (CYAD)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Celyad (CYAD – Research Report), with a price target of $43.00. The company’s shares closed last Monday at $12.28. According to TipRanks.com, White is a

H.C. Wainwright Keeps Their Buy Rating on TG Therapeutics (TGTX)

H.C. Wainwright analyst Edward White reiterated a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target of $20.00. The company’s shares closed last Monday at $7.68. According to TipRanks.com, White is a 5-star analyst

GlycoMimetics (GLYC) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on GlycoMimetics (GLYC – Research Report), with a price target of $18.00. The company’s shares closed last Monday at $5.96. According to TipRanks.com, White is a

TRACON Pharmaceuticals (TCON) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research Report) today and set a price target of $2.00. The company’s shares closed last Monday at $0.42, close to its 52-week low of $0.28. According

Analysts’ Top Healthcare Picks: Dynavax (DVAX), Idera (IDRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dynavax (DVAX – Research Report) and Idera (IDRA – Research Report) with bullish sentiments. Dynavax (DVAX) In a report released today, Edward

H.C. Wainwright Reaffirms Their Buy Rating on G1 Therapeutics (GTHX)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on G1 Therapeutics (GTHX – Research Report), with a price target of $72.00. The company’s shares closed last Monday at $22.38. According to TipRanks.com, White is